Intensity Therapeutics Files 8-K
Ticker: INTS · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1567264
| Field | Detail |
|---|---|
| Company | Intensity Therapeutics, Inc. (INTS) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
INTENSITY THERAPEUTICS FILED AN 8-K - DETAILS UNCLEAR
AI Summary
Intensity Therapeutics, Inc. filed an 8-K on September 10, 2025, to report "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This 8-K filing indicates that Intensity Therapeutics has reported an event requiring immediate disclosure to the SEC, though the specifics are not detailed in the provided text.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate financial implications or significant corporate changes detailed in the provided text.
Key Players & Entities
- INTENSITY THERAPEUTICS, INC. (company) — Registrant
- September 10, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1 Enterprise Drive, Suite 430 (address) — Principal Executive Offices
- Shelton, CT (location) — Principal Executive Offices City and State
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.
When was this 8-K filing submitted to the SEC?
The filing was submitted on September 10, 2025.
What is the principal executive office address for Intensity Therapeutics, Inc.?
The principal executive office is located at 1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779.
In which state is Intensity Therapeutics, Inc. incorporated?
Intensity Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Intensity Therapeutics, Inc.?
The SEC file number is 001-41109.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-09-10 16:04:09
Key Financial Figures
- $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto
Filing Documents
- intensity-20250910.htm (8-K) — 23KB
- 0001567264-25-000093.txt ( ) — 142KB
- intensity-20250910.xsd (EX-101.SCH) — 2KB
- intensity-20250910_lab.xml (EX-101.LAB) — 23KB
- intensity-20250910_pre.xml (EX-101.PRE) — 13KB
- intensity-20250910_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On September 10, 2025, Intensity Therapeutics, Inc. (the "Company") announced an update on it's INVINCIBLE-4 study. The update reported that a pathological complete response ("pCR") was observed in the first patient evaluated in Cohort A, where each patient received two doses of INT230-6 eight days apart, followed by the standard of care immunochemotherapy, and that to date, the safety profile looks favorable in Cohort A. However, some patients in Cohort A experienced localized skin irritation near the tumor site and therefore, new patient enrollment has been paused to evaluate the data collected and to implement necessary adjustments prior to reopening patient enrollment.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 10, 2025 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer